(Q79390358)
Statements
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals (English)
Martin Markowitz
Javier O Morales-Ramirez
Bach-Yen Nguyen
Colin M Kovacs
Roy T Steigbigel
David A Cooper
Ralph Liporace
Robert Schwartz
Robin Isaacs
Lucinda R Gilde
Larissa Wenning
Jing Zhao